Drug Trial Radar · NCT06884085
A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B
Last checked: Nov 19, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
Jul 12, 2025
Primary completion
Aug 13, 2025
Study completion Aug 13, 2025
Sponsor
- Lead sponsor
- Addpharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-227 in healthy subjects.
Conditions
- Primary Hypertension
Interventions
Co-administration of AD-227A and AD-227BDrug
Co-administration of AD-227A 1Tab. and AD-227B 1Tab., Per Oral
Administration of AD-227Drug
Administration of AD-227 1Tab., Per Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum concentration of drug in plasma (Cmax)Time frame: pre-dose (0hour) to 72hours
- Area under the plasma concentration-time curve during dosing interval (AUCt)Time frame: pre-dose (0hour) to 72hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Central Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.